![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CURIS, INC. ANNOUNCES NEW CANCER PROGRAMS, FORMATION OF CHINA-BASED SUBSIDIARY
CURIS, INC. ANNOUNCES NEW CANCER PROGRAMS, FORMATION OF CHINA-BASED SUBSIDIARY
September 13, 2006
Curis, Inc., a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced that it has formed a wholly foreign-owned enterprise form of subsidiary in Shanghai, China. Earlier in 2006, Curis had initiated development work on several proprietary cancer programs through its relationship with Shanghai ChemPartner, a leading Chinese medicinal chemistry contract researcher. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=29615&full=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct